Gilman Hill Asset Management LLC boosted its holdings in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 6.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,602 shares of the biopharmaceutical company’s stock after acquiring an additional 785 shares during the quarter. Gilman Hill Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $758,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of BMY. American National Bank increased its stake in Bristol-Myers Squibb by 36.0% during the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 508 shares during the last quarter. Welch Investments LLC increased its stake in Bristol-Myers Squibb by 3.9% during the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 79 shares during the last quarter. Crestwood Advisors Group LLC acquired a new stake in Bristol-Myers Squibb during the first quarter worth $116,000. Blue Chip Partners Inc. increased its stake in Bristol-Myers Squibb by 0.8% during the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 17 shares during the last quarter. Finally, Proficio Capital Partners LLC increased its stake in Bristol-Myers Squibb by 29.6% during the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 504 shares during the last quarter. 68.88% of the stock is owned by institutional investors.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 6,000 shares of the business’s stock in a transaction on Wednesday, August 2nd. The shares were purchased at an average price of $55.94 per share, with a total value of $335,640.00. Following the completion of the acquisition, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by company insiders.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at 63.36 on Friday. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $63.55. The firm’s 50-day moving average price is $58.94 and its 200-day moving average price is $56.02. The stock has a market capitalization of $103.91 billion, a P/E ratio of 23.14 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.01. The company had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The company’s revenue was up 5.6% on a year-over-year basis. During the same period last year, the firm earned $0.69 earnings per share. Equities research analysts anticipate that Bristol-Myers Squibb Company will post $2.98 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be paid a $0.39 dividend. The ex-dividend date of this dividend is Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.46%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 56.73%.
A number of brokerages have recently weighed in on BMY. BidaskClub raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. Vetr cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 price objective for the company. in a research note on Tuesday, August 22nd. Deutsche Bank AG set a $55.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, July 17th. Credit Suisse Group set a $58.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Wednesday, August 16th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Wednesday, July 12th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $62.20.
ILLEGAL ACTIVITY WARNING: This news story was reported by BBNS and is the property of of BBNS. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://baseballnewssource.com/markets/gilman-hill-asset-management-llc-grows-position-in-bristol-myers-squibb-company-bmy/1605306.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with our FREE daily email newsletter.